New malaria vaccine shows promise in african trial
NCT ID NCT07385287
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new malaria vaccine in 180 healthy adults aged 18-50 in Burkina Faso. The vaccine uses weakened malaria parasites that stop growing in the liver, so they cannot cause blood-stage infection. Participants receive either one or two doses of the vaccine or a placebo, and researchers will monitor them for malaria infection over 24 weeks to see if the vaccine provides protection.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA (PLASMODIUM FALCIPARUM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Groupe de Recherche Action en Santé (GRAS), Unité de Recherche Clinique de Banfora 06 BP 10248
RECRUITINGOuagadougou, 06, Burkina Faso
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a single shot of a genetically weakened malaria parasite train the body to fight off the real thing?
- Could a Liver-Stage malaria vaccine shield mothers and babies?
- Cancer drug could supercharge malaria treatment and beat resistance
- Smart wristbands may spot malaria before symptoms strike
- Malaria drug resistance confirmed in ethiopia: study raises alarm
- One shot to stop malaria? new injection tested in rwanda